1-20 of 113
Authors: Séverine Vermeire
Journal Article
Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical Program
Inflammatory Bowel Diseases, izaf036, https://doi.org/10.1093/ibd/izaf036
Published: 28 February 2025
Journal Article
Guidance for Fecal Microbiota Transplantation Trials in Ulcerative Colitis: The Second ROME Consensus Conference
Inflammatory Bowel Diseases, izaf013, https://doi.org/10.1093/ibd/izaf013
Published: 11 February 2025
Journal Article
Dietary Carrageenan Amplifies the Inflammatory Profile, but not Permeability, of Intestinal Epithelial Cells from Patients With Crohn’s Disease
Inflammatory Bowel Diseases, izae306, https://doi.org/10.1093/ibd/izae306
Published: 24 December 2024
Journal Article
MIP4IBD: An Easy and Rapid Genotyping-by-Sequencing Assay for the Inflammatory Bowel Diseases Risk Loci Get access
Inflammatory Bowel Diseases, Volume 31, Issue 3, March 2025, Pages 786–799, https://doi.org/10.1093/ibd/izae289
Published: 09 December 2024
Journal Article
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
Inflammatory Bowel Diseases, izae253, https://doi.org/10.1093/ibd/izae253
Published: 25 October 2024
Journal Article
Benefit-Risk Trade-offs and Patient Preferences for Therapy Selection in Ulcerative Colitis: a Multicountry Preference Study
Inflammatory Bowel Diseases, izae162, https://doi.org/10.1093/ibd/izae162
Published: 10 August 2024
Journal Article
Eosinophil Depletion as a Potential Therapeutic Strategy in Acute and Chronic Intestinal Inflammation Based on a Dextran Sulfate Sodium Colitis Model Get access
Inflammatory Bowel Diseases, Volume 31, Issue 1, January 2025, Pages 169–177, https://doi.org/10.1093/ibd/izae168
Published: 06 August 2024
Journal Article
Ustekinumab and Vedolizumab Exposure Is Unaffected by Pharmacogenetic Determinants of Anti-TNFs Pharmacokinetics
Inflammatory Bowel Diseases, Volume 30, Issue 5, May 2024, Pages 874–875, https://doi.org/10.1093/ibd/izae035
Published: 06 April 2024
Journal Article
EDITOR'S CHOICE
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
Inflammatory Bowel Diseases, Volume 30, Issue 12, December 2024, Pages 2245–2258, https://doi.org/10.1093/ibd/izae024
Published: 09 March 2024
Journal Article
Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn’s Disease: A Belgian Multicentric Cohort Study
Inflammatory Bowel Diseases, Volume 30, Issue 12, December 2024, Pages 2289–2296, https://doi.org/10.1093/ibd/izad315
Published: 12 January 2024
Journal Article
Appearance of the Bowel and Mesentery During Surgery Is Not Predictive of Postoperative Recurrence After Ileocecal Resection for Crohn’s Disease: A Prospective Monocentric Study
Inflammatory Bowel Diseases, Volume 30, Issue 10, October 2024, Pages 1686–1695, https://doi.org/10.1093/ibd/izad227
Published: 04 October 2023
Journal Article
EDITOR'S CHOICE
Geography Influences Susceptibility to SARS-CoV-2 Serological Response in Patients With Inflammatory Bowel Disease: Multinational Analysis From the ICARUS-IBD Consortium
Inflammatory Bowel Diseases, Volume 29, Issue 11, November 2023, Pages 1693–1705, https://doi.org/10.1093/ibd/izad097
Published: 24 June 2023
Journal Article
Induction and Maintenance Treatment With Upadacitinib Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 Study Results
Inflammatory Bowel Diseases, Volume 29, Issue 9, September 2023, Pages 1421–1430, https://doi.org/10.1093/ibd/izac260
Published: 16 January 2023
Journal Article
Screening Failure in a Large Clinical Trial Centre for Inflammatory Bowel Diseases: Rates, Causes, and Outcomes
Inflammatory Bowel Diseases, Volume 29, Issue 9, September 2023, Pages 1440–1445, https://doi.org/10.1093/ibd/izac227
Published: 09 November 2022
Journal Article
The Modified Mucosal Inflammation Noninvasive Index and Endoscopic Remission in Adults With Crohn’s Disease
Inflammatory Bowel Diseases, Volume 29, Issue 7, July 2023, Pages 1170–1174, https://doi.org/10.1093/ibd/izac235
Published: 09 November 2022
Journal Article
Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program
Inflammatory Bowel Diseases, Volume 29, Issue 1, January 2023, Pages 27–41, https://doi.org/10.1093/ibd/izac084
Published: 07 November 2022
Journal Article
Health-Related Quality of Life Outcomes With Tofacitinib Treatment in Patients With Ulcerative Colitis in the Open-Label Extension Study, OCTAVE Open
Inflammatory Bowel Diseases, Volume 29, Issue 9, September 2023, Pages 1370–1379, https://doi.org/10.1093/ibd/izac222
Published: 15 October 2022
Journal Article
Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib
Inflammatory Bowel Diseases, Volume 29, Issue 1, January 2023, Pages 85–96, https://doi.org/10.1093/ibd/izac063
Published: 01 June 2022
Journal Article
Corrigendum to: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study
Inflammatory Bowel Diseases, Volume 28, Issue 5, May 2022, Page 817, https://doi.org/10.1093/ibd/izab270
Published: 12 November 2021
Journal Article
EDITOR'S CHOICE
Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBD
Inflammatory Bowel Diseases, Volume 28, Issue 8, August 2022, Pages 1135–1142, https://doi.org/10.1093/ibd/izab257
Published: 09 November 2021
